# Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer

> **NCT00632333** · PHASE1 · UNKNOWN · sponsor: **Teikyo University** · enrollment: 9 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **BIOLOGICAL:** URLC10, TTK, KOC1, VEGFR1, VEGFR2, cisplatin, fluorouracil

## Key facts

- **NCT ID:** NCT00632333
- **Lead sponsor:** Teikyo University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-02
- **Primary completion:** 2011-12
- **Final completion:** 2012-03
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2011-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00632333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00632333, "Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00632333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*